Drug also recommended for approval in head and neck squamous cell carcinoma
News
Deliver on your potential
Highlighting the real difference that individual sales people can deliver to both patients and HCP’s, the PharmaTimes Sales Awards offers a crucial opportunity for learning and development against an ever changing landscape.
Are you the hottest agency in town?
You should be! Enter now and be the most talked about agency of 2019
Q2 results roundup – 27 July
The latest financial results from Amgen, Astellas, AZ, BMS and Celgene
Clinigen buys global rights to Horizon’s Imukin
The UK’s Clinigen Group has bought global rights to rare disease therapy Imukin from Horizon Pharma, for an undisclosed amount.
Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC
Takeda’s Alunbrig has beaten Pfizer’s Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.
NICE backing for Keytruda in classical Hodgkin lymphoma
The National Institute for Health and Care Excellence has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund (CDF) for a subgroup of people with relapsed or refractory classical Hodgkin lymphoma.
Time is running out – ENTER NOW
The prestigious PharmaTimes Marketer of the Year competition closes for entries in a matter of weeks. It only takes a few seconds to fill out the online entry form and you don’t need to do anything else until the day of the competition, so if you are thinking of entering, do it now!
GSK ups guidance and unveils major restructure
GlaxoSmithKline has upped its expectations for the year after a strong performance by its vaccines division in the second quarter and the delay of a potential generic version of Advair in the US.
Keytruda extends survival in first-line head and neck cancer trial
MSD’s Keytruda significantly extended overall survival when used as monotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients expressing PD-L1.
Opioid analgesics, Z-drugs linked to harmful effects in dementia patients
Medicines commonly prescribed to dementia patients have been linked to an increase in harmful side-effects, according to new research involving the University of Exeter and King’s College London.
ViiV unveils positive data for two-drug HIV regimens
ViiV Healthcare has unveiled positive clinical data for two two-drug HIV regimens ay the 22nd International AIDS conference in Amsterdam, showing long-term efficacy and non-inferiority to a current standard of care.
US approves AbbVie/Neurocrine’s uterine pain drug
AbbVie and Neurocrine have announced the US approval of Orilissa, the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.
HPV jab will be given to boys in England, gov’t confirms
The government has confirmed that boys in England will be vaccinated against the human papilloma virus in line with recent recommendations from the Joint Committee on Vaccination and Immunisation (JCVI).
JCVI backs HPV jab for boys
Government advisors are recommending that the national HPV immunisation programme in England should include boys as well as girls.
